CoChat

Smoldering multiple myeloma requiring treatment: time for a new definition?

Open access
Dispenzieri, Angela, Stewart, A. Keith, Chanan-Khan, Asher, Rajkumar, S. Vincent, Kyle, Robert A., Fonseca, Rafael, Kapoor, Prashant, Bergsagel, P. Leif, McCurdy, Arleigh, Gertz, Morie A., Lacy, Martha Q., Lust, John A., Russell, Stephen J., Zeldenrust, Steven R., Reeder, Craig, Roy, Vivek, Buadi, Francis, Dingli, David, Hayman, Suzanne R., Leung, Nelson, Lin, Yi, Mikhael, Joseph, Kumar, Shaji K. · 2013 · Blood
Cited by 82

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myeloma-related events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-08-520890

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 82

Metadata

Authors
Dispenzieri, A., Stewart, A. K., Chanan-Khan, A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A., Gertz, M. A., Lacy, M. Q., Lust, J. A., Russell, S. J., Zeldenrust, S. R., Reeder, C., Roy, V., Buadi, F., Dingli, D., Hayman, S. R., Leung, N., Lin, Y., Mikhael, J., & Kumar, S. K.
Venue
Blood
Published
2013-12-19
Volume
122
Issue
26
Pages
4172-4181
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2134215460
Cited by
82
References
11
FWCI
8.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Smoldering multiple myeloma requiring treatment: time for a new definition? https://app.cochat.ai/papers/10.1182/blood-2013-08-520890
The paper
Dispenzieri, A., Stewart, A. K., Chanan-Khan, A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A., Gertz, M. A., Lacy, M. Q., Lust, J. A., Russell, S. J., Zeldenrust, S. R., Reeder, C., Roy, V., Buadi, F., Dingli, D., Hayman, S. R., . . . Kumar, S. K. (2013). Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. https://doi.org/10.1182/blood-2013-08-520890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.